Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
Status:
Terminated
Trial end date:
2016-06-10
Target enrollment:
Participant gender:
Summary
This study is designed to determine whether proton beam radiotherapy plus Sorafenib compared
to Sorafenib alone will produce the best results for treating patients with Hepatocellular
Carcinoma.